CBM588 with Nivolumab and Ipilimumab for Advanced Kidney Cancer
This study is testing CBM588 capsules in combination with nivolumab and ipilimumab for patients with advanced kidney cancer, including clear cell and sarcomatoid types, that has spread. CBM588 is a live biotherapeutic that may help improve how well immunotherapy works. Nivolumab and ipilimumab are immunotherapies (medicines that help your body's immune system fight cancer) that aim to stop cancer cells from growing and spreading. This trial will look at the safety, side effects, and best dose of these treatments. Success will be measured by how safe the combination is and how many side effects occur. The study plans to enroll 28 participants, and its current recruitment status is unclear.
- Study design
- This is a phase I interventional study, meaning it's an early-stage trial looking at safety and dosage. It plans to enroll 28 participants.
- What's involved
- You would take CBM588 capsules by mouth and receive nivolumab and ipilimumab intravenously (IV). You would also undergo blood sample collection, CT scans, and bone scans throughout the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- The incidence of adverse events (side effects) will be measured for up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06399419
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Recruiting
PHASE1Ages 18+InterventionalTreatmentOsel, Inc.
~28 participants
Updated 2024-05-30 on ClinicalTrials.gov
What's tested:Biospecimen CollectionBone ScanCBM588 CapsulesComputed TomographyIpilimumabMagnetic Resonance Imaging
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose limiting toxicity (DLT)
Measured over Up to 28 days
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Alex Chehrazi-Raffle, MD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Documented informed consent of the participant and/or legally authorized representative
Assent, when appropriate, will be obtained per institutional guidelines
Agreement to allow the use of archival tissue from diagnostic tumor biopsies
If unavailable, exceptions may be granted with study principle investigator (PI) approval
Eastern Cooperative Oncology Group (ECOG) ≤ 2
Age ≥ 18 years
Histologically confirmed renal cell carcinoma with clear cell renal cell carcinoma component or sarcomatoid component
Advanced (not amenable to curative surgery or radiation therapy) or metastatic (American Joint Committee on Cancer \[AJCC\] stage IV) renal cell carcinoma with intermediate- or poor-risk disease by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria
No prior systemic therapy for renal cell carcinoma (RCC) with the following exception:
One prior adjuvant or neoadjuvant therapy for completely resectable RCC if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 to prior anti-cancer therapy
Absolute neutrophil count (ANC) ≥ 1500/uL without granulocyte colony-stimulating factor support
White blood cell count ≥ 2500/uL
Platelets ≥ 100,000/uL without transfusion
Hemoglobin ≥ 8 g/dL
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases
Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN)
Serum albumin ≥ 2.8 g/dl
Prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test \< 1.3 x the laboratory ULN
Serum calculated creatinine clearance ≥ 50mL/min using the Cockcroft-Gault equation
Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 5 months after the last dose of nivolumab for women with childbearing potential, and 7 months after the last dose of nivolumab for men
Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \< 55 years-of-age must have a serum follicle stimulating (FSH) level \> 40 mIU/mL to confirm menopause).
Note: Documentation may include review of medical records, medical examinations, or medical history interview by study site
Exclusion
Prior treatment with ipilimumab and/or nivolumab
Current use, or intent to use, probiotics, yogurt, or bacterial fortified foods during the period of treatment
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
Active interstitial lung disease (ILD)/pneumonitis or history of ILD/pneumonitis requiring treatment with systemic steroids
Known medical condition (e.g., a condition associated with diarrhea or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results
Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment
Administration of a live, attenuated vaccine within 30 days before first dose of study treatment
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
Any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days before first dose of study treatment. Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (e.g., contrast allergy) is also allowed
Active infection requiring systemic treatment. Acute or chronic hepatitis B or C infection, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness requiring systemic treatments, or known positive test for tuberculosis infection where there is clinical or radiographic evidence of active mycobacterial infection
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
Malabsorption syndrome
Uncompensated/symptomatic hypothyroidism
Moderate to severe hepatic impairment (Child-Pugh B or C)
Requirement for hemodialysis or peritoneal dialysis
History of solid organ or allogenic stem cell transplant
Other clinically significant disorders that would preclude safe study participation
Any active, known, or suspected autoimmune disease will be excluded, with the following exceptions:
Type 1 diabetes mellitus
Hypothyroidism only requiring hormone replacement
Skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment
Conditions not expected to recur in the absence of an external trigger
Pregnant or lactating females
Inability to swallow tablets/capsules or unwillingness or inability to receive IV administration
Previously identified allergy or hypersensitivity to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies. Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption are also excluded
Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
Exclusion of subjects with a history of myocarditis or congestive heart failure (as defined by New York Heart Association Functional Classification III or IV), as well as unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction 6 months prior to study entry
Exclusion of subjects whose baseline pulse oximetry is less than 92% on room air
Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
What this trial measures
- Dose limiting toxicity (DLT)Up to 28 days
Toxicities at least possibly related to study agent will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.
- Maximum tolerated dose (MTD)Up to 28 days
MTD estimate will be the highest dose with the occurrence of DLT in no more than 1 out of 6 of the patients.
- Incidence of adverse events (AEs)Up to 3 years
AEs will be graded using CTCAE. Summaries will be provided overall and by dose group. The number and percentage of subjects reporting treatment-emergent AEs (TEAE) will be summarized overall and by the worse CTCAE grade, with a breakdown by dose. The number and percentage of subjects reporting TEAEs considered related to each study drug will be summarized.